AGC Biologics has unveiled a new Cell and Gene Technologies Division, hubbed at the CDMO’s Milan Cell and Gene Center of Excellence.
The Milan site offers 30 years of experience in cell and gene therapy, with nine commercial approvals and hundreds of GMP batches produced successfully. The site was tasked with the commercial manufacturing of the lentiviral vectors for Autolus Therapeutics' Aucatzyl as well as the lentiviral vector and genetically modified cell drug product for Orchard Therapeutics’ Lenmeldy.
The 140,000-square-foot facility offers complete end-to-end services, including R&D and innovation teams supporting initial development and early clinical phases, expanded large-scale viral vector suites with scales up to 2,000 L, new cell therapy suites, and a dedicated floor for quality control, which performs all necessary tests in-house.
The new division will also feature expanded global capabilities, including AGC's Longmont, Colorado facility and the new Yokohama, Japan facility, which will begin cell therapy operations in July 2025.
Luca Alberici, currently the general manager of the Milan Center of Excellence, will oversee the division.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!